It is possible that highly metastasized breast tumors might have acquired additional genetic changes causing resistance to treatment with PARP inhibitors. Therefore, we suggest that PARP inhibitors might be more useful in the prophylactic treatment of women carrying the gene responsible for this form of inherited breast cancer.